Adma Biologics IncMost Recent.Company & Industry OverviewsADMA Biologics: Wall Street Projects Robust Revenue GrowthADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest Pharmaceuticals Corporation. .Company & Industry OverviewsWhy ADMA Biologics Stock Soared YesterdayYesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price.
.Company & Industry OverviewsADMA Biologics: Wall Street Projects Robust Revenue GrowthADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest Pharmaceuticals Corporation.
.Company & Industry OverviewsWhy ADMA Biologics Stock Soared YesterdayYesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price.
